Addition of CMO, Medical Director Chris Polage, MD, and enhancements in clinical operations position Company for success in the clinical development of ALX1 in bronchiectasis

医学总监克里斯·波拉奇（ChrisPolage）医学博士（CMO）的加入以及临床操作的增强，使该公司在支气管扩张症ALX1的临床开发中取得了成功

MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology. .

北卡罗来纳州莫里斯维尔，2024年3月7日/PRNewswire/-Vast Therapeutics今天宣布任命医学博士、MBA保罗·布鲁因伯格为首席医疗官。Bruinenberg博士在呼吸医学和孤儿疾病领域拥有30多年的临床开发管理经验。这一任命以及最近增加的微生物学家和临床诊断专家医学博士克里斯·波拉奇（ChrisPolage）担任医学总监，大大增强了该公司在肺部传染病和医学微生物学方面的临床开发专业知识。。

'Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization,' said Nate Stasko, Chief Executive Officer at Vast Therapeutics. 'He's been here before. His early-stage clinical experience in cystic fibrosis and non-cystic fibrosis bronchiectasis patient populations is a perfect match for our drug candidates that we believe will reshape the respiratory infectious disease landscape.'.

Vast Therapeutics首席执行官内特·斯塔斯科（NateStasko）说，保罗的发展经验将指导Vast Therapeutics成功过渡到临床阶段的组织他以前来过这里。他在囊性纤维化和非囊性纤维化支气管扩张患者人群中的早期临床经验与我们的候选药物完美匹配，我们相信这将重塑呼吸道传染病的格局。”。

'It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria,' commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics. 'The high unmet medical need in this therapeutic area is significant.

Vast Therapeutics首席医疗官保罗·布鲁因伯格（PaulBruinenberg）评论道：“加入一家拥有公认IND的公司，这是一个绝佳的机会，它可以提供一种新的治疗方式，对由铜绿假单胞菌和非结核分枝杆菌引起的慢性感染具有良好的疗效。”这一治疗领域未满足的医疗需求很高。

I am excited to advance our nebulized therapy to maximize clinical outcomes for these patients without concerns of renal toxicity and emergence of antibiotic resistance.' .

我很高兴推进我们的雾化治疗，以最大限度地提高这些患者的临床疗效，而不必担心肾毒性和抗生素耐药性的出现。”。

Vast plans to initiate its Phase 1 clinical development program in Q2 2024 and one or more proof-of-concept studies in subjects with bronchiectasis in 2025.

Vast计划在2024年第二季度启动其第一阶段临床开发计划，并在2025年对支气管扩张症患者进行一项或多项概念验证研究。

Paul Bruinenberg, MD, MBA – Chief Medical Officer

Paul Bruinenberg，医学博士，MBA–首席医疗官

Dr. Bruinenberg has over 30 years' experience in the pharmaceutical and biotechnology industry. He brings a wealth of respiratory infectious disease experience researching rare diseases like cystic fibrosis (CF), non-CF bronchiectasis (NCFB), tuberculosis (TB) and non-tuberculosis mycobacteria (NTM).

Bruinenberg博士在制药和生物技术行业拥有30多年的经验。他带来了丰富的呼吸道传染病研究经验，研究罕见疾病，如囊性纤维化（CF），非CF支气管扩张（NCFB），结核病（TB）和非结核分枝杆菌（NTM）。

His career includes development of several inhaled therapies including the approval of Pulmozyme® as the first mucolytic for CF as well as the early development of inhaled liposomal ciprofloxacin for the treatment of chronic Pseudomonas aeruginosa infections..

他的职业生涯包括开发几种吸入疗法，包括批准Pulmozyme®作为CF的第一种粘液溶解剂，以及早期开发用于治疗慢性铜绿假单胞菌感染的吸入脂质体环丙沙星。。

Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections. Previously, he held medical leadership roles at Eagle Pharmaceuticals, Aradigm Corporation, Astellas and Roche, having a key role in the development and approval of 12 new drugs (Pulmozyme®, Pretonamid®, Globocef®, Rocephin®, Quinodis® Bosentan®, Xolair®, CellCept®, Zenapax®, Belrapzo®, Bendeka®, and Ryanodex®).

最近，Bruinenberg博士担任结核病联盟的高级医疗官员，领导针对分枝杆菌感染的临床开发。此前，他曾在Eagle Pharmaceuticals，Aradigm Corporation，Astellas和Roche担任医学领导职务，在12种新药（Pulmozyme®，Pretonamid®，Globocef®，Rocephin®，Quinodis®Bosentan®，Xolair®，CellCept®，Zenapax®，Belrapzo®，Bendeka®和Ryanodex®）的开发和批准中发挥关键作用。

Dr. Bruinenberg is a graduate of the medical school of the University of the Stellenbosch, South Africa and obtained two MBAs from the University of Nijenrode in the Netherlands and Rochester University in the USA..

Bruinenberg博士毕业于南非斯特伦博世大学医学院，并获得了荷兰尼杰罗德大学和美国罗切斯特大学的两个MBA学位。。

Chris Polage, MD – Medical Director

医学博士Chris Polage–医学总监

Dr. Polage is a physician-scientist and board-certified medical microbiologist with NIH clinical research training and over 15 years of experience leading top academic clinical laboratories. His award-winning research and publications have been cited more than 2500 times in the medical and scientific literature and changed medical practice regarding the diagnosis and treatment of C.

Polage博士是一名医师科学家和董事会认证的医学微生物学家，接受过NIH临床研究培训，拥有领导顶级学术临床实验室的15年以上经验。他的获奖研究和出版物在医学和科学文献中被引用了2500多次，并改变了有关C的诊断和治疗的医疗实践。

difficile, an urgent antimicrobial resistance threat. Before coming to Vast, he was Medical Director of the Duke University Clinical Microbiology Laboratory where he oversaw specialized testing for a broad array of patient populations including CF and NCFB patients. Dr. Polage is a diagnostics expert for the NIAID/NIH Antimicrobial Resistance Leadership Group and an adjunct Associate Professor of Pathology at Duke University.

艰难梭菌是一种紧急的抗菌素耐药性威胁。在加入Vast之前，他是杜克大学临床微生物学实验室的医学主任，负责监督包括CF和NCFB患者在内的广泛患者群体的专业测试。Polage博士是NIAID/NIH抗菌素耐药性领导小组的诊断专家，也是杜克大学病理学副教授。

He received his Doctor of Medicine from the University of New Mexico with residency and fellowship training at the University of Colorado and University of Utah/ARUP Laboratories, including two years of medical microbiology with a special focus on mycobacterial testing..

他在新墨西哥大学获得了医学博士学位，并在科罗拉多大学和犹他大学/奥雅纳实验室接受了住院医师和研究员培训，包括两年的医学微生物学，特别关注分枝杆菌检测。。

About Vast Therapeutics

关于Vast Therapeutics

Vast is a life science company focused on breaking the debilitating cycle of infection and chronic inflammation in respiratory diseases. This cycle affects patients across the entire spectrum of human life, ranging from children with rare orphan diseases like Cystic Fibrosis to adults with highly prevalent diseases like chronic obstructive pulmonary disease (COPD).

Vast是一家生命科学公司，专注于打破呼吸道疾病中感染和慢性炎症的衰弱循环。这个周期影响整个人类生活的患者，从患有罕见孤儿疾病（如囊性纤维化）的儿童到患有高度流行疾病（如慢性阻塞性肺病（COPD））的成年人。

We believe our product candidates may provide an effective treatment for patients infected with Pseudomonas aeruginosa, NTM, and other drug-resistant microbes. .

我们相信我们的候选产品可能为感染铜绿假单胞菌，NTM和其他耐药微生物的患者提供有效的治疗。。

Contact:

联系人：

Nathan Stasko

Nathan Stasko

Chief Executive Officer

首席执行官

Vast Therapeutics, Inc.

Vast Therapeutics公司。

nstasko@vasttherapeutics.com

nstasko@vasttherapeutics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vast-therapeutics-expands-leadership-team-with-appointment-of-dr-paul-bruinenberg-as-chief-medical-officer-302082981.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/vast-therapeutics-expands-leadership-team-with-appointment-of-dr-paul-bruinenberg-as-chief-medical-officer-302082981.html

SOURCE Vast Therapeutics, Inc.

SOURCE Vast Therapeutics公司。